Details for Patent: 6,949,571
✉ Email this page to a colleague
Which drugs does patent 6,949,571 protect, and when does it expire?
Patent 6,949,571 protects FYCOMPA and is included in two NDAs.
This patent has forty-eight patent family members in twenty-six countries.
Summary for Patent: 6,949,571
Title: | 1,2-dihydropyridine compounds, process for preparation of the same and use thereof |
Abstract: | The present invention provides a novel compound having an excellent AMPA receptor inhibitory action and/or kainate inhibitory action. A compound represented by the following formula, a salt thereof or hydrates thereof. ##STR1## In the formula, Q indicates NH, O or S; and R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are the same as or different from each other and each indicates hydrogen atom, a halogen atom, a C.sub.1-6 alkyl group or a group represented by the formula --X-A (wherein X indicates a single bond, an optionally substituted C.sub.1-6 alkylene group etc.; and A indicates an optionally substituted C.sub.6-14 aromatic hydrocarbocyclic group or 5- to 14-membered aromatic heterocyclic group etc.). |
Inventor(s): | Nagato; Satoshi (Chiba, JP), Ueno; Kohshi (Ibaraki, JP), Kawano; Koki (Ibaraki, JP), Norimine; Yoshihiko (Ibaraki, JP), Ito; Koichi (Chiba, JP), Hanada; Takahisa (Ibaraki, JP), Ueno; Masataka (Ibaraki, JP), Amino; Hiroyuki (Ibaraki, JP), Ogo; Makoto (Ibaraki, JP), Hatakeyama; Shinji (Ibaraki, JP), Groom; Anthony John (Wiltshire, GB), Rivers; Leanne (Kent, GB), Smith; Terence (Cambridgeshire, GB) |
Assignee: | Eisai Co., Ltd. (Tokyo, JP) |
Application Number: | 10/296,719 |
Patent Claim Types: see list of patent claims | Compound; Use; Composition; |
Recent additions to Drugs Protected by US Patent 6,949,571
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Product | Substance | Delist Req. | Patent Expiration | Usecode | Patented / Exclusive Use |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Catalyst Pharms | FYCOMPA | perampanel | TABLET | 202834 | Oct 22, 2012 | RX | Yes | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | U-106 | TREATMENT OF EPILEPSY | |
Catalyst Pharms | FYCOMPA | perampanel | TABLET | 202834 | Oct 22, 2012 | RX | Yes | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | U-2088 | TREATMENT OF PARTIAL-ONSET SEIZURES WITH OR WITHOUT SECONDARILY GENERALIZED SEIZURES IN PATIENTS WITH EPILEPSY | |
Catalyst Pharms | FYCOMPA | perampanel | TABLET | 202834 | Oct 22, 2012 | RX | Yes | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | U-2089 | TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY | |
Catalyst Pharms | FYCOMPA | perampanel | TABLET | 202834 | Oct 22, 2012 | RX | Yes | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | U-2428 | TREATMENT OF PARTIAL-ONSET SEIZURES WITH OR WITHOUT SECONDARILY GENERALIZED SEIZURES IN PATIENTS WITH EPILEPSY 4 YEARS OF AGE AND OLDER | |
Catalyst Pharms | FYCOMPA | perampanel | TABLET | 202834 | Oct 22, 2012 | RX | Yes | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | U-2429 | TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY 12 YEARS OF AGE AND OLDER | |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Type | >RLD | >Patent No. | >Product | >Substance | >Delist Req. | >Patent Expiration | >Usecode | >Patented / Exclusive Use |
Drugs Protected by US Patent 6,949,571
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Catalyst Pharms | FYCOMPA | perampanel | SUSPENSION;ORAL | 208277-001 | Apr 29, 2016 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | TREATMENT OF PARTIAL-ONSET SEIZURES WITH OR WITHOUT SECONDARILY GENERALIZED SEIZURES IN PATIENTS WITH EPILEPSY 4 YEARS OF AGE AND OLDER | ⤷ Try a Trial | ||
Catalyst Pharms | FYCOMPA | perampanel | SUSPENSION;ORAL | 208277-001 | Apr 29, 2016 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | TREATMENT OF PARTIAL-ONSET SEIZURES WITH OR WITHOUT SECONDARILY GENERALIZED SEIZURES IN PATIENTS WITH EPILEPSY | ⤷ Try a Trial | ||
Catalyst Pharms | FYCOMPA | perampanel | SUSPENSION;ORAL | 208277-001 | Apr 29, 2016 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY | ⤷ Try a Trial | ||
Catalyst Pharms | FYCOMPA | perampanel | SUSPENSION;ORAL | 208277-001 | Apr 29, 2016 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | TREATMENT OF EPILEPSY | ⤷ Try a Trial | ||
Catalyst Pharms | FYCOMPA | perampanel | SUSPENSION;ORAL | 208277-001 | Apr 29, 2016 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY 12 YEARS OF AGE AND OLDER | ⤷ Try a Trial | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 6,949,571
Foriegn Application Priority Data | ||
Foreign Country | Foreign Patent Number | Foreign Patent Date |
Japan | 2000-175966 | Jun 12, 2000 |
United Kingdom | 0022483 | Sep 13, 2000 |
PCT Information | |||
PCT Filed | June 08, 2001 | PCT Application Number: | PCT/JP01/04857 |
PCT Publication Date: | December 20, 2001 | PCT Publication Number: | WO01/96308 |
International Family Members for US Patent 6,949,571
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Austria | 420862 | ⤷ Try a Trial | |||
Australia | 2001262723 | ⤷ Try a Trial | |||
Australia | 6272301 | ⤷ Try a Trial | |||
Brazil | 0111596 | ⤷ Try a Trial | |||
Canada | 2412172 | ⤷ Try a Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |